Home › Trials › NCT06700343

Comparing ABP 692 with Ocrevus for treating relapsing-remitting multiple sclerosis

A Randomized, Double-blind, Parallel-group Study to Compare Pharmacokinetics, Pharmacodynamics, Clinical Effects, and Safety Between ABP 692 and Ocrevus® (Ocrelizumab) in Subjects With Relapsing-remitting Multiple Sclerosis

PHASE3 · Amgen · NCT06700343

This study is testing if a new treatment called ABP 692 can work as well as Ocrevus for people with relapsing-remitting multiple sclerosis by looking at how it affects brain lesions over 24 weeks.

Quick facts

PhasePHASE3
Study typeInterventional
Enrollment444 (estimated)
Ages18 Years to 99 Years
SexAll
SponsorAmgen (industry)
Drugs / interventionsOcrelizumab
Locations108 sites (Mobile, Alabama and 107 other locations)
Trial IDNCT06700343 on ClinicalTrials.gov

What this trial studies

This study aims to compare the pharmacokinetics and pharmacodynamics of ABP 692 with Ocrelizumab, a well-established treatment for relapsing-remitting multiple sclerosis (RRMS). Participants will be assessed for the suppression of new active brain lesions over a 24-week period using magnetic resonance imaging (MRI). The study will include patients diagnosed with RRMS who meet specific inclusion criteria and will exclude those with certain contraindications or other forms of MS. The goal is to establish whether ABP 692 is a comparable alternative to Ocrelizumab.

Who should consider this trial

Good fit: Ideal candidates are individuals diagnosed with relapsing-remitting multiple sclerosis who are neurologically stable and meet the study's inclusion criteria.

Not a fit: Patients with primary progressive or secondary progressive multiple sclerosis, or those with significant medical conditions requiring chronic treatment with immunosuppressants, may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could provide patients with a new, effective treatment option for relapsing-remitting multiple sclerosis.

How similar studies have performed: Other studies have shown success with similar approaches in comparing biosimilars to established treatments, indicating potential for positive outcomes.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

1. Diagnosis of RRMS in accordance with the revised McDonald Criteria 2017 (Thompson et al, 2018).
2. Expanded Disability Status Scale score at screening ≥ 0 and ≤ 5.5 inclusive.
3. Evidence of recent MS activity as defined by the study protocol.
4. Neurologically stable subject, with no relapse for ≤ 28 days before randomization.

Exclusion Criteria:

1. Diagnosis of primary progressive or with secondary progressive MS (Thompson et al, 2018).
2. Multiple sclerosis disease duration of ≥ 10 years in Participants with Expanded Disability Status Scale (EDSS) score of ≤ 2.5 at screening.
3. Any contraindications to study procedures or medications as outlined in the study protocol.
4. Any prohibited medication as defined in the study protocol.
5. Any significant concomitant disease that may require chronic treatment with systemic corticosteroids and/or systemic immunosuppressants during the study.
6. Current or history of any significant medical conditions as described in the study protocol.
7. Any abnormal laboratory blood values as defined in the study protocol.

Where this trial is running

Mobile, Alabama and 107 other locations

+58 more sites — see ClinicalTrials.gov for the full list.

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.

View on ClinicalTrials.gov →

Conditions: Relapsing-remitting Multiple Sclerosis, Neuroscience, Neurology, Neuroimmunology, Immunosuppressants, Ocrelizumab, ABP 692

Last reviewed 2026-05-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.